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SummAry 
Pneumococcal surface protein A  (PspA),  a cell-surface protein present on all strains  of pneu- 
mococci, has been shown to elicit protective antibody responses in mice in the absence of capsular 
polysaccharide. Whereas PspA is polymorphic, considerable cross-reactivity and cross-protection 
have been demonstrated among PspA proteins of pneumococci exhibiting different capsular and 
PspA serotypes. A gene segment encoding the nonrepetitive variable NH2-terminal portion of 
PspA has been cloned into three distinct recombinant Bacille Calmette-Gu6rin (rBCG) vectors, 
allowing for expression  of PspA as a cytoplasmic or secreted protein, or a chimeric exported 
membrane-associated lipoprotein. All rBCG-PspA strains elicited comparable anti-PspA ELISA 
titers,  ranging from 104 to 10  s (reciprocal titers)  in both BALB/c and C3H/HeJ mice. How- 
ever, protective responses were observed only in animals immunized with the rBCG-PspA vac- 
cines expressing PspA as a secreted protein or chimeric exported lipoprotein. In addition, anti- 
PspA immune sera elicited by the rBCG vaccines passively protected X-linked immunodeficient 
mice from lethal challenge with the highly virulent, encapsulated WU2 strain of Streptococcus 
pneumoniae and two additional virulent strains exhibiting heterologous PspA and capsular sero- 
types. These studies confirm previous PspA immunization studies showing cross-protection against 
heterologous serotypes of S. pneumoniae and demonstrate a potential for rBCG-based PspA vac- 
cines to elicit protective humoral responses  against pneumococcal disease in humans. 
S 
treptococcus imeumoniae is the most frequent causative agent 
of bacterial pneumonia and otitis media, one of the major 
causes of meningitis, and a primary source of death world- 
wide (1-3).  Among infants and young children, acute otitis 
media (AOM) is the most common disease caused by this 
pathogen (4--6). It has been estimated that approximately three 
fourths of all children experience at least one episode of AOM 
and that >50% of these cases are caused by S. pneumoniae. 
S. pneumoniae,  therefore,  accounts for >106 cases of middle 
ear infection in the United States alone in children under 2 
yr of age (1). In addition, S. pneumoniae  continues to be a 
major respiratory tract  pathogen of adults,  especially the 
elderly, and is responsible for '~40,000 deaths per year among 
adults in the United States (7). The increasing frequency world- 
wide of antibiotic-resistant S. pneumoniae, as well as the mor- 
bidity and mortality associated with pneumococcal disease, 
argue for prophylactic vaccination as a means to protect against 
infection. 
The pneumococcal vaccine currently available is a polyva- 
lent vaccine composed of unconjugated, purified, pneumo- 
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coccal capsular polysaccharides. Whereas this vaccine has been 
shown to be protective in adults (8, 9), it is of limited use 
in infants and children since the latter populations are poor 
responders to polysaccharide  antigens and generally fail to 
generate protective antibodies  to  isolated polysaccharides 
(10-13). Protein antigens, in contrast to polysaccharides, have 
the advantage that they are immunogenic in infants as well 
as adults. The need for a pneumococcal vaccine that is effec- 
tive in young children and infants has prompted studies to 
identify protein antigens of the pneumococcus that are able 
to elicit protective immune responses. The pneumococcal sur- 
face protein A (PspA) 1 is a protein antigen of S. pneumoniae 
which has been shown to elicit protective immunity in the 
mouse model for pneumococcal disease (14-16). 
PspA is present on all pneumococcal  isolates (17). Although 
a great number of antigenic variants of PspA exist, PspA also 
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cross-protection against strains of different PspA and capsular 
types (18, 19, and Briles, D. E., and L. S. McDaniel, manu- 
script in preparation).  Furthermore,  mAbs to PspA provide 
passive protection in mice against fatal pneumococcal infec- 
tion (16, 18, 20). In addition, it has been shown that X-linked 
immunodeficient (Xid) mice, which like young children are 
unable to mount immune responses to polysaccharide vac- 
cines (21), produce antibodies to PspA (22). The anti-PspA 
antibodies are able to protect against death even in the ab- 
sence of other antipneumococcal antibodies. Taken together, 
these studies suggest that  the PspA protein may be a good 
candidate  antigen  for incorporation  into  a  pneumococcal 
vaccine. 
Bacille Calmette-Gurrin  (BCG),  an attenuated  strain  of 
Mycobacterium bovis, offers a number of advantages as a vac- 
cine vehicle for delivering foreign antigens such as PspA. BCG 
is already the most widely administered live vaccine,  having 
been given as an antituberculosis vaccine to >2.5 billion people 
worldwide (23-24). Because of its safety record, it is suitable 
for immunization of young children and infants. BCG is also 
relatively inexpensive to produce and has strong immuno- 
stimulatory properties that produce long-lasting sensitization 
to mycobacterial antigens. 
Recently developed genetic systems for the expression of 
foreign antigens in mycobacteria (25-28) have enabled the 
evaluation of rBCG as a vaccine delivery vehicle.  Subsequent 
studies have demonstrated that rBCG can elicit antigen-specific 
systemic antibody responses after parenteral or mucosal (in- 
tranasal)  immunization and that these antibodies are protec- 
tive (29, 30, 30a).  For example, humoral antibodies to the 
outer-surface protein A (OspA) ofBorrelia lmrgdo~feri  dicited 
by a rBCG vaccine have been shown to be protective against 
challenge with/g burgdorferi  in a mouse model for Lyme bor- 
reliosis (29, 30). Also, BCG expressing gp63 from Leishmania 
major have been shown to induce strong protective responses 
in a mouse model for Leishmaniasis  (30) and antibodies to 
tetanus toxin fragment C expressed in rBCG have been shown 
to protect against challenge with tetanus toxin (31). Thus, 
rBCG  vaccines  expressing  PspA  (rBCG-PspA)  were  con- 
structed to test their efficacy as candidate vaccines against pneu- 
mococcal disease.  In this paper we report on protective hu- 
moral responses elicited by such rBCG-PspA vaccines in the 
mouse model for pneumococcal disease. 
Materials and Methods 
Construction of  BCG/Escherichia coli Shuttle Expression Vectors  for 
Expression ofpspA.  Plasmid vectors pMV206 and pMV261 (25) 
are the parental plasmids for all the plasmid constructs  described 
below. Plasmid pMV206 is composed of DNA cassettes encoding 
Kanamycin resistance (Kan), an E. coil origin of replication (Erep), 
a mycobacterial plasmid replicon derived from plasmid pAL5000 
(Mrep),  and a multiple  cloning  site (MCS) all assembled into a 
mycobacterial-E, coli  shuttle vector, pMV261 is similar to pMV206 
but also includes the promotor, ribosomal binding site (RBS), and 
initial six codons of the BCG heat shock protein 60 (hsp60) gene 
inserted between XbaI and BamHI sites of the multiple  cloning 
site of plasmid pMV206. Plasmid pRB26 differs from pMV261 in 
that it contains only the BCG hsp60 promotor but not the hsp60 
RBS nor any of the hsp60 coding sequence (29). Plasmid expres- 
sionAecretion vector p2619s was constructed by inserting a PCR- 
derived DNA segment encoding the Myocobacterium  tuberculosis  19- 
kD (Mtb19) RBS and 5' lipoprotein  signal peptide downstream 
from the hsp60 promotor of  phsmid pRB26. For two of the plasmids 
encoding papA, pMV261-pspA33 and p2619-pst2A33, a pspA gene 
segment encoding the NHz-terminal region of the PspA protein, 
spanning amino acids +4 to  +299, was amplified by PCR from 
DNA derived from S. traeuraoniae  strain Rxl (32) and cloned be- 
tween the BamHI and SalI sites in the MCS of plasmids pMV261 
and p2619 to yield plasmids pMV261-pspA33 and p2619-pspA33, 
respectively, (see Fig. 1); 5' BamHI and 3' SalI restriction sites were 
incorporated into the primers for subcloning. The predicted size 
of the PspA-derived peptide encoded by these plasmids, 33 kD, is 
larger than that encoded by the originalpspA truncation  mutation 
as reported by Talkington et al. (pJY2008) (33). For plasmid pRB26- 
pspA33, the cloned pspA fragment encodes a protein that extends 
from the first residue of the PapA leader sequence (- 31) through 
residue +299 (see Fig. 1). A PCR-amplified BamHI-SallpspA gene 
segment (pspA69) encoding  the full-length  69-kD  PspA protein 
without signal peptide was cloned into another vector, the hsp60- 
/acZ fusion vector pSL26 which is a derivative of plasmid pMV261. 
pSL26 incorporates the 5' region ofE. coli lacZ (encoding the first 
71 codons) upstream of the first six hsp60 codons of pMV261. The 
resulting vector was termed pSL26-pspA69. 
Growth of BCG  and  Transformation of Shuttle Plasmids into 
BCG.  All liquid cultures ofBCG substrain Pasteur 1173P2 were 
grown at 37~  in stationary  tissue culture  flasks (25 cm  2 with 
5-10 ml or 75 cm  z with 15-25 ml) or roller bottles (490 cm  2 with 
100-200 ml or 1,700 cm  2 with 200-500 ml) using Dubos (Difco 
Laboratories, Detroit, MI) media supplemented with 1/10th volume 
of AD enrichment consisting of 5% BSA fraction V (Sigma Chem- 
ical Co., St. Louis, MO), 2% dextrose, and 0.85% sodium chlo- 
ride. Liquid culture media included 0.02% Tween 80 (T80) to pre- 
vent clumping of BCG cells. BCG colonies were grown at 37~ 
on Middlebrook 7H10 agar media (Difco Laboratories) supplemented 
with 1/10th volume of AD enrichment. For transformation, BCG 
cultures were grown to densities of ~107 CFU/ml, sedimented at 
4,000g, and washed twice by resuspension and centrifugation (4,000 
g) in 10% glycerol at 4~  and finally resuspended in 1/20th of 
the original culture volume of cold 10% glycerol. Then 200/~1 
of the cold BCG suspension was mixed with plasmid DNA (50-500 
ng) in a prechilled 0.2-cm electroporation cuvette and transformed 
using the Biorad Gene Pulser electroporator  (both from Bio-Rad 
Laboratories, Richmond, CA) at 2.5 kV, 25 mr, and 1,000 W. After 
electroporation,  50/~1 5 x  Dubos media was added to the BCG- 
DNA suspension, and the mixture was incubated at 37~  for I h 
before plating on Middlebrook 7H10 plates supplemented with AD 
enrichment  and kanamycin (15/~g/ml). 
Analysis of  pspA Expression in rBCG.  BCG transformants were 
grown to mid-logarithmic phase in Dubos liquid media containing 
kanamycin (15/~g/ml). After washing the cells in PBS plus 0.05% 
T80, the cell suspension was concentrated 20-fold in RIPA buffer 
(1% NP-40, 0.5% Deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) 
to lyse the cells. Culture lysates were analyzed by SDS-PAGE and 
Western blot with the PspA-specific  mAb Xi126 (15). Expression 
of PspA by rBCG was compared with an S. pneumoniae lysate de- 
rived from strain Rxl and to purified recombinant  PspA protein 
kindly provided by Dr. P. H. McVerry (Connaught  Laboratories 
Inc.,  Swiftwater,  PA). Protein  bands reacting  with Xi126 were 
visualized  after  incubation  with  a  secondary  antibody  (goat 
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sham, Arlington Heights, IL) enhanced chemiluminescence (ECL) 
system. 
Immunizations with rBCG Strains.  rBCG cultures were grown 
in roller bottles to optical densities of ~1.2 A~0 U  (=2  x  10  s 
CFU/ml), concentrated 20-fold by centrifugation  at 4,000 g, and 
resuspended in I ml of 15% glycerol. The rBCG glycerol suspen- 
sions were gradually frozen at a rate of -1~  per minute,  from 
4~  to  -40~  and then stored at  -70~  until use. CFU were 
assayed by growing thawed material on Middlebrook 7H10 plates 
plus kanamycin at various dilutions. 
4-6-wk-old female BALB/c and C3H/HeJ mice (The Jackson 
Laboratory, Bar Harbor, ME) were immunized by the intraperitoneal 
route with 106 rBCG CFU in 100/~1 of PBS-T80. 
Anti-PspA Response oflmmunizedMicc  Sera  were collected from 
the tail veins of immunized  mice at 4-wk intervals and pooled for 
each group to monitor antibody responses by ELISAs with purified 
PspA protein (provided by Dr. P. H. McVerry. ELISA plates (Ira- 
toulon 4; Dynatech Laboratories, Inc., Chantilly, VA) were coated 
with 50/~1 of PspA protein (0.1/~g/ml)  in 0.1M carbonate buffer, 
pH 9.6, and incubated for 2-4 h at room temperature or overnight 
at 4~  The antigen solution was removed and plates were incubated 
with blocking solution (0.5% BSA and 0.5% nonfat dry milk in 
H20) for  1 h at room temperature.  Twofold serial dilutions  of 
serum starting  at 1:200 were made in blocking  solution  and 50 
/~1 of each dilution  was added to duplicate wells of the antigen- 
coated plate. After an incubation at room temperature for 1 h, the 
coated plates were washed with PBS plus 0.1% Tween-20 (T20) 
and  incubated  with  50  /~1  of a  1:4,000  PBS-T20 dilution  of 
peroxidase-conjugated goat anti-mouse IgG (Kirkegaard & Perry 
Laboratories, Gaithersburg, MD) secondary antibody for 1 h at room 
temperature.  Color was developed with ABTS substrate reagent 
(Kirkegaard & Perry Laboratories) and measured by absorbance at 
405 nm on a Dynatech ELISA reader. Endpoint titers were defined 
as the highest  dilution  at which the Aos values were twice the 
values for preimmune  sera diluted  1:200 in blocking  solution. 
Mouse Protection Experiments in rBCG-Pst~A Immunized Mice. 
BALB/c and C3H/HeJ mice immunized with rBCG-PspA vaccine 
strains were challenged intraperitoneally  with 104 CFU (100  x 
LDs0) of the highly lethal S. pneumoniae strain WU2 (34). Im- 
mediately after challenge, samples of the S. Imeumoniae challenge 
inoculum were plated on trypticase soy blood agar plates to deter- 
mine the CFU and verify the challenge dose. Deaths were recorded 
at 24-h intervals. Most deaths occurred between days 2 and 4 after 
challenge, however the mice were observed for a total of 10-12 d 
as indicated. 
Passive Protection Experiments with Antisera  from rBCG-PspA Im- 
munized Mice.  Anti-PspA antisera collected from mice vaccinated 
with rBCG containing  p2619-pspA33 was administered passively 
in 0.1-ml volumes into CBA/N mice by the intraperitoneal route 
at a 1:40 dilution  on days 0, 2, and 3. Mice were challenged by 
the intravenous route on day 0 with 500 CFU of each of five highly 
virulent strains of S. pneumoniae (35), in a total volume of 0.2 ml, 
1 h  after passive administration  of the antibody.  The virulent 
S. Imeumoniae challenge strains varied either in their capsular or 
PspA serotype. The mice were observed for survival for a period 
of 12 d after challenge with the virulent  S. pneumoniae. 
Results 
Expression and Localization of PspA in rBCG.  Previously 
we have shown that rBCG can elicit both humoral and eel- 
lular immune responses to foreign antigens expressed in the 
cytoplasm of rBCG (25, 31). More recently, we reported on 
the development of rBCG expression vectors that allow for 
the export or secretion of foreign antigens from rBCG by 
fusing the recombinant  proteins  to the Mtb19 lipoprotein 
signal peptide (29).  In the case of at least one antigen,  the 
OspA of/~ burgdorferi,  secretion and surface expression resulted 
in much stronger antigen-specific  and protective humoral and 
cellular responses than was possible with cytoplasmic expres- 
sion in rBCG. 
A  PspA  gene  segment  (pspA33)  encoding  the  NH2- 
terminal variable protective domain of the PspA protein from 
S. pneumoniae strain Rxl (type 25 PspA [36]) spanning amino 
acids  +4 to  +299 of the protein, was cloned into rBCG ex- 
pression vectors pMV261  and  p2619s  to  result  in  vectors 
pMV261-pspA33  and p2619-pspA33.  In both plasmids,  the 
DNA fragment encoding the NH2-terminal portion of PspA 
did not contain the PspA signal peptide~ For pMV261-pspA33, 
the pspA33  gene segment was fused to the first six codons 
of the cytoplasmically expressed BCG hsp60 gene product. 
For p2619-pspA33, the pspA33 fragment was fused to the 5' 
region  of the  Mtb19  structural  gene  encoding  the  NH2- 
terminal 28 amino acids including the 21-residue signal pep- 
tide for the M. tuberculosis Mtb19 surface-expressed lipopro- 
tein. In addition to constructing these two plasmids,  a slightly 
larger pspA33  gene segment (extending from the  -31 res- 
idue of PspA through residue + 299, thus including the nat- 
ural PspA signal peptide, as well as the PspA ribosomal binding 
site), was cloned into vector pRB26, resulting in a nonfused 
pspA33 gene segment expressed in BCG (pRB26-pspA33). 
In all three vectors, expression of the pspA33 gene segment 
was driven by the BCG hsp60 promoter on a multi-copy extra 
chromosomal plasmid vector (Fig. 1). In addition, a gene seg- 
ment encoding the full-length 69-kD PspA protein, with or 
without the 5' region encoding the PspA signal peptide, was 
cloned into a variety of BCG expression vectors that all uti- 
lized the BCG ~p60 promoter  (Fig.  2 legend). 
Expression of PspA gene segments from all of the rBCG 
expression vectors was confirmed by SDS-PAGE and Western 
blot analysis  of whole-cell BCG lysates.  The highest  level 
of expression was seen in rBCG transformed with the cyto- 
plasmic  expression  vector  pMV261-pspA33  encoding  the 
NH2-terminal  protective  PspA33  domain  without  signal 
peptide. Cytophsmically expressed PspA33 (C-PspA) in rBCG- 
pMV261-pspA33 accounted for "~15% of the total BCG pro- 
tein, and the amount produced was two- to fivefold greater 
than that seen with rBCG carrying plasmids pP,  B26-pspA33 
or p2619-pspA33 encoding either PspA33 with the natural 
pneumococcal signal peptide (S-PspA) or the Mtb19 lipopro- 
rein signal peptide (L-PspA),  respectively (Fig.  2). 
Expression  of the  full-length  69-kD  PspA protein  was 
seen only in  lysates of BCG strains  transformed  with  the 
pSL26-pspA69 plasmid (Fig. 2). Whereas rBCG-pSL26-pspA69 
expressed low levels of a full-length  Hsp60-LacZ-PspA fu- 
sion protein without  signal peptide,  this rBCG strain was 
dif~cult to maintain  in culture and was therefore not pur- 
sued further. The inability to obtain stable rBCG strains ex- 
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Figure 1.  BCG/E. coil shuttle expression vectors used to express recombinant antigens.  Plasmid vector pMV206,  the parent vector of all vectors 
used in this study, is composed of DNA cassettes encoding Kanamycin resistance (/Can), an E, cell origin of replication (Erep), a mycobacterial plasmid 
replicon derived from plasmid pALS000 (Mre?) and a multiple cloning site all assembled into a BCG/E. cell shuttle vector as described by Stover et 
al. (25). Expression  vector derivative pMV261,  also includes  the promoter, ribosomal binding site (RBS),  and initial six codons of the BCG hsp60 
gene cloned between the XbaI and BamHI site of pMV206. Plasmid pRB26 differs from pMV261  in that it only includes the BCG hsp60 promoter. 
Plasmid p2619s is a derivative of pRB26 and includes a DNA segment encoding the Mtb19 RBS and 5' lipoprotein signal peptide downstream from 
the hsp60 promoter. A pspA gene segment encoding the NH2-terminal 33-kD region of the pst2A gene from S. pneuraoniae strain Rxl (34) was PCR 
amplified with or without the 5' region ~ncoding  the PspA signal peptide and cloned into either pMV261,  pRB26,  or p2619s. 
pressing the full-length PspA protein with its natural COOH- 
terminal anchor domain would suggest that expression  of 
the pneumococcal repetitive anchor domain is deleterious 
to BCG. 
rBCG expressing all the different PspA33 constructs were 
fractionated by the Triton X-114 detergent phase partitioning 
method to determine the cellular location of the different 
recombinant PspA33 polypeptides (29)  (data  not shown). 
Only the chimeric PspA lipoprotein expressed from vector 
p2619-psM33 was localized to the BCG membrane. The PspA 
lipoprotein expressed from the p2619 vector was also acces- 
sible to surface labeling with anti-PspA  antibody as deter- 
mined by flow cytometry studies, which is consistent with 
previous studies utilizing the same vector to express OspA 
from R  burgdorferi as a recombinant surface antigen in BCG 
(29). Whereas most of the PspA protein expressed  from vectors 
pMV261-pspA33  and pRB26-pspA33 was found in the cyto- 
plasmic fractions, small amounts were also found in the media 
suggesting limited transport or secretion of the PspA protein 
with or without the signal peptide (data not shown). This 
unexpected finding, which cannot be explained presently, could 
not be accounted for by autolysis of the rBCG since hsp60, 
a cytoplasmic heat shock protein which is produced in abun- 
dance by BCG, was not detected in the same media fractions. 
Immunization with rBCG Expressing PsFA as a Secreted Pro- 
tein or Chimeric Lipoprotein  Elicits Protective Humeral Immunity 
in both BALB/c and C3  H Mice.  C3H and BALB/c mice were 
immunized intraperitoneally with 106 CFU of the rBCG- 
PspA vaccines described above and evaluated for PspA-specific 
IgG responses. Both strains  of mice mounted strong anti- 
body responses to PspA regardless of whether PspA was ex- 
pressed in the cytoplasm, exported to the surface of BCG, 
or secreted (Fig. 3).  In all cases, reciprocal ELISA titers to 
PspA ranged from 103 to  104 after  a single immunization 
and increased  10-fold  (104  tO  l0  s reciprocal  titers)  after  a 
booster immunization at ,v17 wk postprimary immuniza- 
tion. However,  only the rBCG vaccines expressing PspA as 
a secreted protein (pRB26-pspA) or as a chimeric lipoprotein 
(pMV2619-pspA) elicited protective immunity against pneu- 
mococcal challenge with 100 LDs0 of virulent pneumococci 
(strain WU2) in both C3H and BALB/c mice (Fig. 3). The 
level of protection against pneumococcal challenge ranged 
from 50%  for C3H mice to as high as 90%  for BALB/c. 
In this particular experiment, the  secreted  form of PspA 
afforded a slightly higher level of protection than the lipi- 
dated PspA. It is surprising that whereas comparable ELISA 
end-point titers to PspA were observed in animals immunized 
with  the  nonsecreted, cytoplasmic rBCG  containing the 
pMV261-pspA clone, only modest protection against pneu- 
mococcal challenge was seen, and only in the CH3 strain 
of mice. Immunization with rBCG expressing the unrelated 
OspA antigen as a lipoprotein did not protect against pneu- 
mococcal challenge in either C3H or BALB/c mice. 
In a subsequent experiment, C3H and BALB/c mice were 
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pneumococcal challenge was antibody mediated and not de- 
pendent in part on simultaneous inflammatory responses in- 
duced by live BCG, serum was collected from rBCG-PspA- 
immunized mice and administered passively to CBA/N mice 
before challenge with a lethal dose of S. pneumonia~ CBA/N, 
which carry the Xid trait,  are highly sensitive to pneumo- 
coccal infection (21, 22). Three doses of anti-PspA antibody 
diluted  1:40  and  administered  to  CBA/N  mice  by  in- 
traperitoneal injection, protected against challenge with 100 
times the lethal dose of three highly virulent strains of pneu- 
mococci that differed in either their PspA or capsular sero- 
types. Whereas the anti-PspA antiserum directed against the 
type 25 PspA serotype (the type cloned into BCG) protected 
against challenge with S. pneumoniae  strains  expressing het- 
erologous PspA serotypes (types 1,  13,  and 24),  it did not 
protect against passive challenge with a S. pneumoniae strain 
expressing PspA type 18, as shown (Table 1). The anti-PspA 
antibody prevented death or delayed the time of death by at 
least 2 d. CBA/N mice that did not receive any passive serum 
died  within  2  d  of challenge.  Furthermore,  virtually  all 
CBA/N mice given passive intraperitoneal injections of anti- 
OspA antiserum also died within 2 d of challenge (Table 1). 
Figure 2.  Expression  of PspA gene segments in rBCG. rBCG lysates 
were subjected  to SDS-PAGE  (top) and Western blot analysis  with PspA- 
specific  mAb Xi126 (bottom). Expression  of the PspA33  gene  product from 
vector pMV261 (261::ps/2A33)  was estimated to be "~100 ng per 106 CFU 
of rBCG whereas expression from pRB26 (RB26::pspA33) and p2619s 
(2619::ps/~133)  was five-  and twofold  less, respectively.  A whole cell  lysate 
derived from  S. pneumoniae strain Rxl and purified  preparations of  recom- 
binant PspA  protein were  run as positive  controls. The 261::hc which ex- 
presses Lac rather than PspA  in the same  BCG background strain was run 
as a negative  control. Expression  of a full-length Hsp60-LacZ-PspA  fusion 
protein without a signal  peptide  was observed  with rBCG  containing vector 
pSL26::pspA69. 
In a subsequent experiment, C3H and BALB/c mice were 
immunized intraperitoneally with  106 CFU of either rBCG 
expressing  the secreted (S-PspA) or the lipidated  (L-PspA) form 
of PspA, and were challenged with a lethal dose of virulent 
pneumococci to confirm the protective efficacy of these two 
rBCG vaccine strains.  Once again,  reciprocal titers to PspA 
ranged from 103 to 104 after a single immunization  and in- 
creased  10-fold (104 to  105 reciprocal titers)  after a booster 
immunization  at  17 wk.  When  the  mice were challenged 
with  100x  LDs0 virulent  pneumococci,  80%  of the C3H 
and 100% of the BALB/c mice receiving either of the rBCG- 
PspA vaccine strains  survived (Fig.  4).  A  small percentage 
of the control mice survived presumably due to nonspecific 
immunity  to S. pneumoniae. 
I~sive Transfer  of  Antibody from rBCC,-PspA-immunized Mice 
Protects CBA/N Mice  from Lethal Challenge with Diverse Strains 
Discussion 
Previous studies have shown that  antibody raised against 
purified PspA protein, a surface antigen present on all S. pneu- 
moniae clinical  isolates (17),  protects against fatal S. pneumo- 
niae infection in mice (16, 18, 20, 22). In this report, we dem- 
onstrate that a single inoculation with a live BCG bacterial 
vaccine expressing PspA as a secreted mature protein or a chi- 
meric  exported  lipoprotein  (rBCG-PspA),  followed  by  a 
booster at  17 wk, results in a protective humoral  antibody 
response against  virulent  S. pneumoniae.  These results  lend 
further support to a role for anti-PspA antibodies in protecting 
against pneumococcal infection and demonstrate that BCG 
is a powerful vaccine vehicle for eliciting  such a protective 
response. 
BCG, an attenuated bovine tubercle bacillus used as a vac- 
cine for tuberculosis, offers considerable advantages as a safe, 
live vaccine vehicle for the expression and delivery of protec- 
tive recombinant antigens. It is the most widely used vaccine 
in the world with a low incidence of serious complications, 
it can be given at birth,  and is unaffected by maternal anti- 
bodies (23,  24, 37).  Furthermore,  given that  BCG can ac- 
commodate large pieces  of foreign DNA, it is also possible 
to develop rBCG which allow for the simultaneous expres- 
sion of multiple  protective antigens  derived from different 
pathogens (25, 27, 28, 38, 39). All of these factors are partic- 
ularly important  to consider in the development of a pneu- 
mococcal vaccine that is targeted predominantly  to infants. 
In addition,  it is important  to consider the potential side 
effects associated with a live bacterial vaccine vector such as 
BCG.  The most frequent  adverse  reaction  to BCG is  sup- 
purative  lymphadenitis  (40).  However, it  has  clearly been 
shown in studies conducted with BCG strains  used for ira- 
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Figure 3.  Mice immunized with rBCG-PspA and challenged with S. pneumoniae  are protected against death: challenge experiment No.  1. C3H/HeJ 
and BALB/c mice were immunized and boosted by the intraperituneal route with 106 CFU of rBCG expressing the PspA antigen from S. pneumoniae. 
The recombinant PspA protein contained either an exported,  lipid-acylated mycobacterial lipoprotein sequence (p2619::pspA),  the endogenous PspA 
signal sequence (pRB26::pspA), or no signal sequence (pMV261::pspA). Control mice were inoculated with 106 rBCG expressing a lipid-acylated form 
of the OspA protein from/g burgdorferi  (2619::ospA). (A) Sera were collected every 4 wk as wall as 2 wk postbooster immunization (week 17), pooled 
for each group,  and evaluated for anti-PspA antibody by ELISA.  (/3) 2 wk postboost mice from each group were challenged intraperitoneally with 
104 CFU S. pneumoniae (100  x  LDs0).  Survival was determined in all five groups over the course of 12 d  after challenge. Data are presented as the 
percent survival for a total of 10 mice per experimental group.  For the C3H mice, p  <0.001 for pRB26::pspA and P2619::pspA immunized vs. naive 
mice; p <0.005 for pRB26::pspA and P2619::pspA immunized mice vs. the p2619::ospA immunized control. For the BALB/c mice, p <0.02 for pRB26::pspA 
immunized vs. naive and p <0.05 for P2619::pspA vs. naive mice: p <0.02 for both pRB26::pspA and P2619::pspA vs. p2619::ospA immunized control 
(two-sample rank test [53]). 
munization against tuberculosis,  that reactogenicity  can be 
attributed  to  two important factors relating  to growth of 
the BCG vaccine strain: (a) homogeneity of the vaccine sus- 
pension, and (b) viability of the final product. Other secondary 
factors  such as  the  skill  of the  medical  personnd  in  ad- 
ministering the intradermal vaccine may influence responses 
as well. Whereas the conventional static growth of BCG yields 
a nondispersed,  low viability vaccine preparation that results 
in high reactogenicity,  the growth conditions we have em- 
ployed for the rBCG vaccine preparations, employing roller 
bottles, yield well-dispersed  cultures of high viability (29). 
Based on other published studies well-dispersed  cultures of 
rBCG could result in high immunogenicity without the as- 
sociated clinical  complications (41). 
Whereas BCG would seem to be particularly well-suited 
to didting cellular responses and not humoral responses since 
it is an intracellular pathogen which resides within macro- 
phages, recent efforts have focused on improving the ability 
of rBCG vaccines to elicit  strong humoral responses as well 
by developing vector  systems  that  allow for the export  or 
secretion of foreign antigens in BCG. For example,  expres- 
sion of the OspA antigen of/t  burgdorferi as an exported, 
chimeric membrane-associated lipoprotein in rBCG resulted 
in a strong,  long-lasting and protective humoral response in 
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Figure 4.  Mice immunized with rBCG-PspA and challenged with S. pneumoniae are protected against death: challenge experiment  No. 2. C3H/HeJ 
and BALB/c mice were immunized and boosted by the intraperitoneal  route as in challenge experiment  No. 1. This time only the rBCG expressing 
PspA with the endogenous PspA signal sequence (pRB26::pspA)  or the lipid-acylated mycobacterial signal sequence (p2619:'pspA) were used as vaccines. 
Control mice were inoculated  with 10  ~ rBCG expressing a lipid-acylated form of the OspA protein  from/~ burgdorferi  (2619::ospA) as in experiment 
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munized mice vs. the p2619::ospA immunized controls  (two-sample  rank  test  [54]). 
mice (29, 30a). To evaluate the potential for rBCG vaccines 
to elicit  a humoral immune response to PspA,  the NH2- 
terminal half of the PspA protein was expressed in BCG as 
a secreted protein or as a chimeric membrane-associated li- 
poprotein by fusion to a 5' DNA sequence encoding the Mtb19 
lipoprotein  signal  peptide;  the  NH2-terminal  portion  of 
PspA was expressed as a cytoplasmic protein as well for com- 
parative  purposes. The NH2-terminal region of PspA was 
cloned into BCG since previous studies had demonstrated 
that antibodies targeted to epitopes within this half of the 
protein are protective (33).  Furthermore, expression of the 
complete PspA antigen in rBCG was toxic to the bacteria 
unless the PspA signal peptide was deleted and replaced with 
the NH2-terminal  75 amino acids of the/3-galactosidase pro- 
tein, for reasons  that are unclear. 
Antibody responses against PspA were observed in BALB/c 
and C3H/HeJ mice with all rBCG vaccines. Whereas peak 
antibody ELISA titers elicited by rBCG expressing PspA with 
or without secretion signal peptides did not differ markedly, 
protective responses were observed only in mice immunized 
with rBCG expressing PspA with its native signal peptide 
or as a fusion with the Mtb19 lipoprotein signal peptide. In 
contrast, prior studies had shown that export of a different 
foreign antigen,/~ burgdo~eri OspA, from the rBCG cytosol, 
seemed to be required for maximum levels of both total anti- 
body and protective immunity against challenge (29). One 
possible explanation for this difference is that, unlike OspA, 
some chimeric PspA is transported across the membrane even 
in the absence of a signal peptide, by some as yet unexplained 
mechanism. This possibility is suggested by limited fraction- 
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Challenge  Strain 
p  Value 
Capsule  Passive  Day of death  vs. 
Name  type  PspA type  antibody  after challenge  control 
WU2  3  1  OspA  2,2,2,2,>6  <0.01  cs 
3  1  PspA  >12,>12,>12,>12,>12  <0.025 tsr 
A66  3  13  OspA  2,2,2,2,2  <0.005  cs 
3  13  PspA  >12,>12,>12,>12,>12  <0.005  tsr 
EF10197  3  18  OspA  2,2,2,2,2  na 
3  18  PspA  2,2,3,4,4  <0.10 tsr 
BG7322  6B  24  OspA  2,2,2,2,2  <0.005  cs 
6B  24  PspA  >12,>12,>12,>12,>12  <0.005 tsr 
All mice were infected with about 500 CFU i.v. Antiserum against the PspA protein was collected  from mice vaccinated with the rBCG-PspA::2619 
strain and administered passively  into CBA/N mice by the intraperitoneal route at a 1/40 dilution on days O, 2, and 3. On day 0, mice were challenged 
intravenously with 500 CFU of five highly virulent strains of S. pneumoniae 1 h after passive administration of antibody (LDs0 for all five strains 
is <;100 organisms). Control CBA/N mice were given antiserum from mice immunized with rBCG-OspA (2619::ospA). 
cs, chi square test; ha, not applicable; tsr, 1 tailed two sample rank test. 
ation studies using the various PspA recombinants (data not 
shown). The cytoplasmic form of PspA might  not be con- 
formationally correct to induce a protective response even in 
its "transported"  form. Conversely, PspA protein expressed 
with its natural  signal peptide or as a chimeric lipoprotein 
anchored to the BCG membrane both induce protective re- 
sponses perhaps since,  in both cases, protective epitopes are 
expressed in the appropriate conformation.  Another possi- 
bility for the difference in terms of protective responses, is 
that the cytoplasmically expressed PspA may be processed by 
the host once the rBCG enters the endosome, and the processed 
form of PspA fails to elicit a protective antibody response. 
These possible explanations require further investigation be- 
yond the scope of this study. In any case, it is clear that the 
antibody response to a cloned antigen in rBCG may vary with 
the particular recombinant protein and how it is expressed. 
This will be an important consideration in the development 
of multivalent  rBCG vaccines. 
The pspA gene fragment, cloned and expressed in the rBCG- 
PspA vaccines, was derived from the Rxl strain ofS. pneumo- 
niae which expresses type 25 PspA (36), one of over 31 PspA 
serotypes as classified by mAb reactivity (17, 42). Whereas 
PspA displays interstrain  variation in its size and in the ex- 
pression of individual antibody-reactive epitopes (17, 43), there 
is a high degree of cross-reactivity among the PspA serotypes 
(18,  19, and Briles,  D. E., and L. S. McDaniel,  manuscript 
in preparation).  Consistent with this observation,  we have 
demonstrated that passive administration of antisera from mice 
immunized  with a rBCG-PspA vaccine protects against le- 
thal challenge with S. pneumoniae strains that express heter- 
ologous PspA serotypes. We have also shown that the rBCG- 
PspA vaccine elicits protection against pneumococci of more 
than one capsular serotype, which again is consistent with 
previous immunogenicity  studies using recombinant  PspA 
proteins  (18,  19).  Whereas  the rBCG-PspA vaccines were 
highly protective against S. pneumoniae challenge,  absolute 
protection was not always observed. The lack of protection 
in some mice was not a function of their failure to respond 
to the rBCG-PspA vaccine;  all mice given the rBCG-PspA 
vaccine mounted strong antigen-specific responses (data not 
shown). 
It should be noted that  CBA/N  mice were used in the 
passive protection studies rather than BALB/c or C3H mice, 
because they have become a standard model for passive pro- 
tection  with  antibody  to pneumococcal antigens  (34,  35, 
44-46).  CBA/N  (Xid)  mice are more susceptible to most 
pneumococcal infections than BALB/c and C3H mice as well 
as most other strains of mice (47).  Thus, protection of Xid 
mice against pneumococcal challenge is a particularly strin- 
gent test of protective efficacy of antipnenmococcal antibodies. 
Furthermore, as another measure of stringency in the passive 
protection assay, Xid mice were challenged intravenously rather 
than intraperitoneally.  Whereas in general strains that are viru- 
lent  intravenously  are  also  virulent  when  inoculated  in- 
traperitoneally  (35, 48),  death occurs a day or two earlier 
in mice challenged by the intravenous route. Another reason 
for choosing to do passive protection  studies in Xid mice 
was that whereas most strains of mice including BALB/c and 
C3H/HeJ have antiphosphocholine antibodies in their serum, 
which is protective against challenge with low inocula of many 
pneumococcal strains (35), antibodies against phosphocho- 
line and most carbohydrates are absent in Xid mice (35). There- 
fore, Xid mice provide the best opportunity to assay for the 
protective effects of spedfic, passively administered antibodies 
in the absence of potentially protective,  endogenous antibodies. 
Nonetheless, recent studies in one of the investigators' labo- 
ratory have demonstrated that the anti-PspA antibodies pro- 
tect against pneumococcal infection regardless of the route 
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(Benton, K., and D.  Briles,  manuscript in preparation). 
Overall, the mouse model for pneumococcal disease is useful 
in terms of identifying and characterizing protective, systemic 
antibody responses that clear disseminated infections. How- 
ever, initial colonization by S. Imeurnoniae occurs along mucosal 
surfaces in the upper respiratory tract, a site where secretory 
antibodies of the IgA subclass may play an important role 
in prevention of mucosal surface colonization by pathogenic 
organisms (49-52). Thus, it may be important to stimulate 
immune responses at mucosal surfaces to block colonization 
and to evaluate the protective efhcacy of such responses  in 
an appropriate challenge model. Recently, we demonstrated 
that mucosal immunization with a live rBCG vaccine ex- 
pressing the OspA antigen results in a prolonged secretory 
IgA response  that is disseminated throughout the mucosal 
immune system, including the upper respiratory tract, as well 
as  a  prolonged and protective systemic immune response 
against a target pathogen (30). A similar approach may now 
be taken with rBCG expressing PspA to determine if mucosal 
delivery of such a vaccine results in protection against pneu- 
mococcal infection and disease. 
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